The grant process involves inviting specific scientists to respond to a request for applications (RFA). Once those materials are received they are reviewed by the Medical Advisory Board and the Board of Directors of the Inflammatory Breast Cancer Research Foundation.
Dr. Beth Overmoyer of Dana-Farber Cancer Institute received a $50,000 grant to pursue her research project, “Validation of Jak2 as Novel Therapeutic Target in Triple Negative Inflammatory Breast Cancer.” Dr. Overmoyer’s project moved her laboratory project into a trial with patients. A medical oncologist focusing on the treatment of breast cancer, Dr. Overmoyer is Assistant Professor of Medicine at Harvard Medical School. In addition to these duties, Dr. Overmoyer is the director of Dana-Farber/Brigham and Women’s Cancer Center’s Inflammatory Breast Cancer Program. Her areas of interest include breast cancer genetics, systemic treatment of breast cancer and treatment of inflammability breast cancer.
A collaboration of the Inflammatory Breast Cancer Research Foundation and the Milburn Foundation made the grant possible.